近日，中国网、中华网、新浪、网易、经济网、医药界等多家权威媒体，对我院神经外科手术机器人技 术进行了深度报道。作为抚矿总医院官方微信，我们特将媒体报道内容与核心亮点整理发布，与广大读 者分享这一来自国家级媒体的认可与见证。 在抚矿总医院神经外科手术室里，一台机器人正以0.2-0.6毫米的精度稳定运行，重新定义着三叉神经 节、颅底等"手术禁区"的风险边界。这正是近日被多家央媒聚焦报道的神经外科手术机器人系统。 一、精度背后，是患者的笑容与安心 三、红色央企底色，筑牢医疗品质根基 针对外界不实传言，报道明确澄清：抚矿总医院是华润健康旗下16家三级医院之一，属于红色央企体系 内的公立医院，并非"私人收购"。 华润健康集团通过专业化管理与集团化运营，探索"更专业、更有效、更经济、更体贴"的医疗运营模 式。这一模式不仅提升单院技术水平，也为区域医疗均质化提供制度保障。 神外主任张永惠介绍，短短两个月，这套系统已成功辅助完成二十余例高难度微创手术，患者预后均良 好。74岁的李奶奶就是受益者之一。她饱受三叉神经痛折磨多年，因药物副作用日渐消瘦。在机器人辅 助下，医生精准完成球囊压迫，术后疼痛即刻消失，3天后顺利出院。 李丽 ...

第36届意大利消化外科年会于11月27日至28日在意大利罗马成功举办。作为欧洲规模最大的消化外科学术盛会之一，本届年会吸引了来自全球各地的顶尖 外科专家参与，以手术直播、录播为核心形式，集中展示胃肠、肝胆、胰腺、食管等消化系统领域的最新外科进展，构建起一个真正意义上的跨国界、高 水准学术对话平台。 意大利消化外科年会历经三十余年发展，已成为全球消化外科领域极具影响力的专业会议。本届会议现场参会者近3000人，线上参与逾1.3万人次。值得 一提的是，在第35届会议期间，大会就已吸引全球超过21万用户在线关注，官网页面浏览量突破106万次，体现出其在世界范围内的广泛学术号召力。 本届年会延续其"外科马拉松"的特色，连线美国、中国、日本、法国、英国等全球多国手术中心，实现连续两天不间断手术直播。截至目前，该会议累计 完成手术直播逾6000台，参与主刀医生超3000名，中国医生在其中扮演了日益重要的角色。 作为中国医药行业的领军企业之一，恒瑞医药已连续两届与意大利消化外科年会达成合作，积极搭建中意消化外科高层次交流桥梁，助力中国顶尖医疗技 术登上世界舞台。 01 搭建高水平国际交流平台， 推动中外消化外科技术共进 在 ...

Core Points - The article announces the continuation of the Global MedTech Awards by Suyu MedTech to promote technological innovation and help innovative companies gain influence starting from 2023 [2] - A supplementary call for entries for innovative companies and products for the year 2025 will be open until the end of 2025 [2] Award Categories and Evaluation Criteria - **Global MedTech Industry Contribution Award**: Targeting leading medical technology companies with approved products widely used in hospitals, demonstrating significant contributions in clinical application, product innovation, economic, and social benefits [4] - **Global Medical Technology Innovation Award**: Aimed at companies with outstanding performance in medical technology innovation, focusing on products or solutions that enhance medical efficiency, improve diagnosis and treatment outcomes, and have market potential and social value [5] - **Global MedTech Rising Star Award**: For growing medical technology companies with unique technological innovation capabilities and strong market development potential [6] - **Global Innovation Medical Device Award**: For innovative medical devices approved by NMPA, FDA, or CE within 2025, recognized for their design, technology, and functionality [7] Application and Selection Process - **Application Phase**: Open from now until December 7, 2025, at 6 PM, where institutions can voluntarily submit their application materials [8] - **Selection Phase**: From now until December 15, 2025, the evaluation committee will review submissions and may contact companies for additional information [8] - **Award Notification**: Expected by December 22, 2025, with results published in an article [9] - **Award Ceremony**: Scheduled for July 2026 at the Zhongguancun Exhibition Center, with further details to be announced [9] Additional Information - Participation in the awards is free of charge, and companies that have previously submitted applications for the first batch should not resubmit [10]

此外，医疗器械领域的镁骨钉产品是宜安科技的另一大亮点业务，其量产应用前景受到机构投资者的重 点关注。公司通过多年研究已掌握相关专利，尽管目前尚未实现放量，但市场及患者群体对镁骨钉产品 存在显著需求。 整体来看，宜安科技在液态金属、机器人、海外基地、医疗器械等多个领域的协同布局，构建起了多维 度、高韧性的业务矩阵，契合当前消费电子升级、机器人产业崛起、全球化分工深化、医疗技术创新等 核心趋势。展望未来，随着株洲新工厂产能逐步释放、液态金属应用场景持续拓展、墨西哥基地建设稳 步推进、机器人业务与医疗器械业务逐步落地，公司有望充分受益于相关产业的快速发展。 液态金属作为宜安科技的核心优势业务，其应用场景的持续拓展成为机构关注的重点话题。据介绍，在 消费电子领域，国内最早推出折叠屏手机的安卓客户从第一代机型就选用了宜安科技的非晶合金(液态 金属)技术，充分印证了公司液态金属技术在产品可靠性、结构支撑性能等方面的显著优势，也体现了 客户对公司技术实力与产品品质的高度认可。此外，在AI服务器散热领域，公司通过多年研究已掌握 相关专利。 在机器人领域，宜安科技基于未来发展战略，已成立具身机器人事业部。该项布局既顺应了机器人 ...

Core Viewpoint - Brazil is seeking to enhance healthcare cooperation with China, aiming to learn from China's advanced experiences to improve health services and the healthcare system's adaptability to climate change [1] Group 1: Healthcare Cooperation - Brazil's Health Minister Padilha expressed the country's willingness to strengthen medical and health cooperation with China [1] - During a visit to China in October, Padilha toured a facility producing dengue fever vaccines and a smart hospital utilizing information technology and artificial intelligence for patient services [1] Group 2: Technological Innovation - Brazil aims to adopt advanced technologies from China in areas such as smart hospitals, vaccine production, and pharmaceutical manufacturing to improve public health [1] - The Brazilian Health Ministry is focused on promoting medical technology innovation to enhance the capacity to respond to natural disasters like hurricanes, floods, droughts, extreme heat, and wildfires [1] Group 3: Community Health Initiatives - In the Amazon region, the Brazilian government is implementing measures such as retrofitting medical ships, utilizing digital technology, and telemedicine to serve local communities [1] - The initiatives aim to improve health levels among residents in remote areas and vulnerable populations [1]

Core Insights - The Jiangsu province is enhancing its healthcare services through innovative medical technologies and improved patient experiences, as evidenced by the inclusion of advanced medical techniques in the national "Good Technology" project [1][2] - The focus on high-quality development in public hospitals aims to meet the health needs of the population by improving medical technology, service models, and patient experiences [1][3] Group 1: Medical Innovations - Two medical technologies from Zhenjiang's hospitals have been recognized in the national "Good Technology" project, showcasing the city's commitment to healthcare innovation [1] - The Zhenjiang First People's Hospital successfully performed a complex finger reconstruction surgery using advanced techniques, marking a significant achievement in local medical capabilities [2][3] Group 2: Public Hospital Development - Zhenjiang is prioritizing the development of specialized capabilities in public hospitals, with multiple national and provincial key specialty units established to enhance healthcare services [3][4] - The integration of traditional Chinese medicine into modern healthcare practices is being emphasized, with new initiatives to promote its application in various medical conditions [4] Group 3: Patient Experience Improvements - The implementation of a health cloud platform allows for the sharing of medical imaging and test results across multiple healthcare facilities, significantly improving patient convenience [5][6] - Community health centers are enhancing patient access to specialists through innovative appointment systems and telemedicine, reducing the need for patients to travel for care [7][8] Group 4: Community Health Initiatives - The "Service for People's Health Action" initiative by Zhenjiang First People's Hospital aims to provide accessible healthcare services in local communities, addressing the challenges of distance and specialist availability [8] - A series of measures have been introduced to streamline healthcare processes and improve patient satisfaction, including free follow-up visits and reduced medical fees [8][9] Group 5: Future Directions - The Zhenjiang health authority is committed to establishing a regional medical center and enhancing public hospital reforms to ensure high-quality healthcare delivery [10]

Core Points - The company Jin Hai Medical Technology (02225) is preparing to participate in the 8th China International Import Expo (CIIE) scheduled for November 5-10, 2025, in Shanghai [1] - During the expo, Jin Hai Medical will jointly launch innovative navigation-based spinal endoscopy technology with Medtronic China, aimed at enhancing precision and intelligence in spinal surgeries [1] - Medtronic is a leading global medical technology company, operating in over 150 countries with more than 90,000 employees [1][2] Company Overview - Medtronic's primary business includes the development, manufacturing, distribution, and sales of medical therapies and services in cardiovascular, neuroscience, surgical, and diabetes fields [2] - Medtronic has established production bases in Shanghai, Changzhou, and Chengdu, China [2] - Since the first CIIE in 2018, Medtronic has participated in the event for seven consecutive years, leveraging its influence to showcase and accelerate the application of its latest innovative medical technologies and products [2]

Table of Contents As filed with the Securities and Exchange Commission on August 20, 2025 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 AETHLON MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 3826 13-3632859 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification N ...

Financial Data and Key Metrics Changes - The company reported Q1 revenue of €8.6 billion, growing 8.4% reported and 4.8% organic, in line with guidance [38] - Adjusted EPS was €1.26, exceeding the midpoint of guidance by €0.03 [42] - Adjusted gross margin was 65.1%, down 80 basis points year over year, but stable compared to Q4 [38] Business Line Data and Key Metrics Changes - Cardiovascular grew 7% this quarter, driven by nearly 50% growth in Cardiac Ablation Solutions [21][22] - Neuroscience grew 3%, with high single-digit growth in neurosurgery and neuromodulation [11][28] - MedSurg grew 2%, with high single-digit growth in Advanced Energy [31] - Diabetes grew 8%, with 11% growth in international markets [34] Market Data and Key Metrics Changes - The U.S. market showed slower growth in certain segments, particularly in diabetes and pelvic health, while international markets performed better [60] - The company expects to ramp up procedures for the SIMPLICITY system following CMS's proposed national coverage decision [25][27] Company Strategy and Development Direction - The company is focused on accelerating growth through innovation and strategic investments in high-growth areas like CAS and Ardian [19][20] - A planned separation of the diabetes business is expected to enhance focus on core businesses and improve revenue and earnings growth [19][37] - New board committees have been established to enhance focus on growth and operational efficiency [48][49] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in accelerating growth in the second half of fiscal 2026, driven by strong demand and new product launches [7][19] - The company anticipates significant revenue growth from its PFA portfolio and other upcoming product launches [13][14] - Management highlighted the importance of maintaining pricing discipline and improving operational efficiencies to support growth [38][45] Other Important Information - The company is increasing investments in R&D, with a 7.7% increase in adjusted R&D spending [40] - The anticipated impact of tariffs has been adjusted, with expectations now at approximately €185 million for fiscal 2026 [44] Q&A Session All Questions and Answers Question: Update on CAS growth and its impact on U.S. growth - Management confirmed that CAS growth is accelerating and will positively impact U.S. growth, despite some segments showing slower growth [56][58] Question: Impact of new board committees on governance and operations - The new committees will provide focused oversight on growth and operational performance, with increased interaction with management expected to drive improvements [68][70] Question: Commitment to CAS annual sales target - Management reaffirmed the commitment to achieving $2 billion in annual CAS sales, indicating strong confidence in the growth trajectory [76][78] Question: Discussion on capital allocation and potential changes - Management indicated that the new board members and committees will facilitate discussions on capital allocation and value creation strategies [81][89] Question: Overall portfolio growth expectations - Management stated that while significant growth opportunities exist, they will not neglect the rest of the business and expect to see incremental growth from various segments [99][100]

Core Points - The article highlights the dedication and contributions of ten exemplary doctors in China, recognized as the "Most Beautiful Doctors" for their commitment to healthcare and patient welfare [1][2] - It emphasizes the spirit of selflessness and compassion in the medical profession, showcasing the impact of these individuals on their communities and the healthcare system [1][9] Group 1: Recognition of Medical Professionals - The "Most Beautiful Doctors" list for 2025 includes ten healthcare professionals who embody the values of life preservation and altruism [1] - These doctors represent nearly 16 million healthcare workers in China, symbolizing the dedication of the medical community [2] Group 2: Individual Stories of Dedication - Liang Chunrong, a village doctor, has spent over 30 years providing healthcare in rural areas, emphasizing affordable treatment for villagers [3] - Wang Yufeng, a pediatric psychiatrist, has dedicated half a century to improving children's mental health and establishing a nationwide service network [4] - Ni Ma La Mao, a Tibetan doctor, has worked tirelessly in high-altitude regions, providing healthcare and education to local herders [5] Group 3: Innovations in Medical Practice - He Jianxing, a thoracic surgeon, has pioneered minimally invasive surgical techniques, significantly improving patient recovery times [6][8] - The article also highlights the importance of continuous medical innovation and the commitment of healthcare professionals to enhance patient care [7] Group 4: Community Impact and Legacy - Nurses and doctors like Xing Shaoyun and Zhang Junqiao have made significant contributions to their communities, with efforts in patient care and emergency response training [9][10] - The article concludes by celebrating the collective efforts of these "Most Beautiful Doctors" in shaping a healthier future for China [10]